These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 23349390)

  • 1. AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model.
    Wunderlich M; Mizukawa B; Chou FS; Sexton C; Shrestha M; Saunthararajah Y; Mulloy JC
    Blood; 2013 Mar; 121(12):e90-7. PubMed ID: 23349390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia.
    Sanjiv K; Calderón-Montaño JM; Pham TM; Erkers T; Tsuber V; Almlöf I; Höglund A; Heshmati Y; Seashore-Ludlow B; Nagesh Danda A; Gad H; Wiita E; Göktürk C; Rasti A; Friedrich S; Centio A; Estruch M; Våtsveen TK; Struyf N; Visnes T; Scobie M; Koolmeister T; Henriksson M; Wallner O; Sandvall T; Lehmann S; Theilgaard-Mönch K; Garnett MJ; Östling P; Walfridsson J; Helleday T; Warpman Berglund U
    Cancer Res; 2021 Nov; 81(22):5733-5744. PubMed ID: 34593524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative utility of NRG and NRGS mice for the study of normal hematopoiesis, leukemogenesis, and therapeutic response.
    Barve A; Casson L; Krem M; Wunderlich M; Mulloy JC; Beverly LJ
    Exp Hematol; 2018 Nov; 67():18-31. PubMed ID: 30125602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity.
    Kruczynski A; Pillon A; Créancier L; Vandenberghe I; Gomes B; Brel V; Fournier E; Annereau JP; Currie E; Guminski Y; Bonnet D; Bailly C; Guilbaud N
    Leukemia; 2013 Nov; 27(11):2139-48. PubMed ID: 23568148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia.
    Di Tullio A; Rouault-Pierre K; Abarrategi A; Mian S; Grey W; Gribben J; Stewart A; Blackwood E; Bonnet D
    Nat Commun; 2017 Nov; 8(1):1679. PubMed ID: 29162833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved chemotherapy modeling with RAG-based immune deficient mice.
    Wunderlich M; Manning N; Sexton C; Sabulski A; Byerly L; O'Brien E; Perentesis JP; Mizukawa B; Mulloy JC
    PLoS One; 2019; 14(11):e0225532. PubMed ID: 31747424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disruption of gap junctions attenuates acute myeloid leukemia chemoresistance induced by bone marrow mesenchymal stromal cells.
    Kouzi F; Zibara K; Bourgeais J; Picou F; Gallay N; Brossaud J; Dakik H; Roux B; Hamard S; Le Nail LR; Hleihel R; Foucault A; Ravalet N; Rouleux-Bonnin F; Gouilleux F; Mazurier F; Bene MC; Akl H; Gyan E; Domenech J; El-Sabban M; Herault O
    Oncogene; 2020 Feb; 39(6):1198-1212. PubMed ID: 31649334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia.
    Leonard SM; Perry T; Woodman CB; Kearns P
    PLoS One; 2014; 9(1):e87475. PubMed ID: 24489920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy.
    Cho BS; Zeng Z; Mu H; Wang Z; Konoplev S; McQueen T; Protopopova M; Cortes J; Marszalek JR; Peng SB; Ma W; Davis RE; Thornton DE; Andreeff M; Konopleva M
    Blood; 2015 Jul; 126(2):222-32. PubMed ID: 26031918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of artemisinins for the treatment of acute myeloid leukemia.
    Drenberg CD; Buaboonnam J; Orwick SJ; Hu S; Li L; Fan Y; Shelat AA; Guy RK; Rubnitz J; Baker SD
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1231-43. PubMed ID: 27125973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity.
    Velu CS; Chaubey A; Phelan JD; Horman SR; Wunderlich M; Guzman ML; Jegga AG; Zeleznik-Le NJ; Chen J; Mulloy JC; Cancelas JA; Jordan CT; Aronow BJ; Marcucci G; Bhat B; Gebelein B; Grimes HL
    J Clin Invest; 2014 Jan; 124(1):222-36. PubMed ID: 24334453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors.
    Feuring-Buske M; Frankel AE; Alexander RL; Gerhard B; Hogge DE
    Cancer Res; 2002 Mar; 62(6):1730-6. PubMed ID: 11912147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways.
    Wu M; Li L; Hamaker M; Small D; Duffield AS
    Haematologica; 2019 Dec; 104(12):2418-2428. PubMed ID: 30975911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Myeloperoxidase Disrupts Mitochondrial Redox Balance and Overcomes Cytarabine Resistance in Human Acute Myeloid Leukemia.
    Hosseini M; Rezvani HR; Aroua N; Bosc C; Farge T; Saland E; Guyonnet-Dupérat V; Zaghdoudi S; Jarrou L; Larrue C; Sabatier M; Mouchel PL; Gotanègre M; Piechaczyk M; Bossis G; Récher C; Sarry JE
    Cancer Res; 2019 Oct; 79(20):5191-5203. PubMed ID: 31358527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curcumin sensitizes response to cytarabine in acute myeloid leukemia by regulating intestinal microbiota.
    Liu J; Luo W; Chen Q; Chen X; Zhou G; Sun H
    Cancer Chemother Pharmacol; 2022 Feb; 89(2):243-253. PubMed ID: 35066694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effectiveness of anti-CD47 antibody and Ara-C combination targeting therapy NOD/SCID mouse of myeloid leukemia].
    Wang YC; Feng L; Yin CY; Ma LN; Wei YW; Wang CM; Sheng GY
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Jul; 15(7):577-82. PubMed ID: 23866283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
    Narayan R; Blonquist TM; Emadi A; Hasserjian RP; Burke M; Lescinskas C; Neuberg DS; Brunner AM; Hobbs G; Hock H; McAfee SL; Chen YB; Attar E; Graubert TA; Bertoli C; Moran JA; Bergeron MK; Foster JE; Ramos AY; Som TT; Vartanian MK; Story JL; McGregor K; Macrae M; Behnan T; Wey MC; Rae J; Preffer FI; Lesho P; Duong VH; Mann ML; Ballen KK; Connolly C; Amrein PC; Fathi AT
    Cancer; 2020 Mar; 126(6):1264-1273. PubMed ID: 31860140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia.
    Zhang CC; Yan Z; Pascual B; Jackson-Fisher A; Huang DS; Zong Q; Elliott M; Fan C; Huser N; Lee J; Sung M; Sapra P
    Neoplasia; 2018 Jan; 20(1):1-11. PubMed ID: 29172076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo.
    Chen Y; Gan D; Huang Q; Luo X; Lin D; Hu J
    Cell Physiol Biochem; 2018; 48(5):2061-2073. PubMed ID: 30099447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML.
    Drenberg CD; Shelat A; Dang J; Cotton A; Orwick SJ; Li M; Jeon JY; Fu Q; Buelow DR; Pioso M; Hu S; Inaba H; Ribeiro RC; Rubnitz JE; Gruber TA; Guy RK; Baker SD
    Nat Commun; 2019 May; 10(1):2189. PubMed ID: 31097698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.